Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Inclusion criteria

• ✓. \>18 years of age
• ✓. Has undergone allo HSCT to treat a B-cell derived hematologic malignancy: accepted alloHSCT regimens include: myeloablative or reduced intensity conditioning from any donor (matched, partially mismatched or cord) and any source (peripheral blood, bone marrow, or cord).
• ✓. T bili ≤ 1.5 mg/dL except for patients with Gilbert's syndrome or hemolysis
• ✓. AST, ALT and alk phos all \< 2.5X ULN
• ✓. Karnofsky performance score ≥ 40
• ✓. ECOG ≤3
• ✓. For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication.
• ✓. Use of two forms of contraception with less than a 5% failure rate or abstinence by all transplanted patients for a minimum of 1 month after the last dose of Idelalisib. For the first 60 days post-transplant, transplant recipients should be encouraged to use non-hormonal contraceptives due to the potential adverse effect of hormones on bone marrow engraftment.

Exclusion criteria